personalized diagnostics

IMMS harnesses for point-of-care diagnostics

At the MEDICA 2016 IMMS is presenting its first approaches for the personalized diagnostics of cancer using a prototype device. It was developed in the three-year research project INSPECT which started in June 2016.

Devices performing rapid, reliable, cost-efficient and automated POC...
Devices performing rapid, reliable, cost-efficient and automated POC diagnostics should look like this in the future. IMMS presents a prototype device with live demonstration to showcase its developments for personalized cancer diagnostics.
Source: IMMS

IMMS focusses on the integration of various sensor principles of different biological and chemical measurands into one integrated electronic device for extensive and precise diagnostics. The work is based on cost-efficient standard semiconductor manufacturing processes (CMOS) which IMMS also uses for these new diagnostic approaches.

IMMS adapts its systems to application-specific needs by means of particular functionalisation of surfaces and the use of biocompatible material. These solutions should pave the way for fast, reliable, cost-efficient and automated in-vitro diagnostics, such as early recognition of cancer.

In the INSPECT research project IMMS is developing systems for the early recognition of breast, cervical, prostate and lung cancers using semiconductor chips as well as immunological and cell-based biotechnological methods. IMMS is working on an interdisciplinary interface between biology and microelectronics for signal processing. In addition, further concepts for microelectronic-based point-of-care diagnostics and for personalized cancer immunotherapies are being investigated. IMMS is currently testing the first prototypes of the miniaturized diagnostic devices. The research partners iba Institut für Bioprozess- und Analysenmesstechnik e.V. Heiligenstadt, Senova Gesellschaft für Biowissenschaft und Technik mbH Weimar, CDA GmbH Suhl and X-FAB Semiconductor Foundries AG Erfurt are contributing to the novel solutions. IMMS is coordinating the consortium.

Funding:
The INSPECT project receives funding from the “Land” of Thüringen and the European Union (European Regional Development Fund (ERDF, German EFRE) under the reference 2015 FE 9159.


Source: IMMS

16.11.2016

Read all latest stories

Related articles

Oncology

Blood test detects early stage pancreatic cancer

Pancreatic cancer is currently very difficult to detect while it is still resectable. A new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and…

Immunotherapy

Toward an “ultra-personalized” therapy for melanoma

With new immunotherapy treatments for melanoma, recovery rates have risen dramatically – in some cases to around 50%. But they could be much higher. A new study led by researchers at the Weizmann…

Oncology

Discovering cancer cell mutations with optimized technologies

Cancer cells often have mutations in their DNA that can give scientists clues about how the cancer started or which treatment may be most effective. Finding these mutations can be difficult, but a…

Related products

Urin analysis

Analyticon Biotechnologies – Urilyzer 500 Pro

Analyticon Biotechnologies AG

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH

Other

INPECO SA – PROTUBE

Inpeco SA

Clinical chemistry

Orion Diagnostica Oy - QuikRead go

Orion Diagnostics Oy